Core Viewpoint - Biogen is expected to report first-quarter 2025 results on May 1, with sales and earnings estimates at $2.24 billion and $3.34 per share, respectively. The company faces challenges from declining sales of multiple sclerosis (MS) drugs, which may be offset by revenues from new drugs [1][2][5]. Sales Performance of MS Drugs - Sales of Biogen's MS drugs, including Tecfidera and Tysabri, are anticipated to decline due to increased competition and the introduction of generic versions in various markets [2][5]. - The Zacks Consensus Estimate for Tecfidera sales is $199.0 million, while the internal estimate is $185.7 million. For Tysabri, the estimates are $363.0 million and $348.6 million, respectively [3][4]. - Vumerity's sales rose in the fourth quarter due to higher demand, with estimates for the first quarter at $141.0 million (Zacks) and $139.8 million (internal) [4]. Impact of Biosimilars and Generics - The decline in MS revenues is expected to be more pronounced in 2025 due to the anticipated entry of biosimilars for Tysabri and generics for Tecfidera in certain European markets [5]. Other Drug Sales - Spinraza's sales improved in the fourth quarter, but demand may have decreased in the first quarter, with estimates at $364.0 million (Zacks) and $338.1 million (internal) [6]. - Sales of Skyclarys for Friedreich's ataxia are expected to rise year-over-year, with estimates at $110.0 million (Zacks) and $111.4 million (internal) [7]. - Zurzuvae's launch has exceeded expectations, with strong patient demand likely contributing to improved sales in the first quarter [8][9]. Alzheimer's Collaboration and Revenues - Revenues from contract manufacturing, royalties, and Alzheimer's collaboration are expected to rise, particularly from the drug Leqembi, which has shown strong sales growth in recent quarters [10][11]. - Leqembi's sales have improved sequentially, with strong growth noted in China and Japan, and it was recently approved in the European Union [11][12]. Overall Revenue Expectations - Overall revenues for the first quarter of 2025 are expected to be negatively impacted by seasonality, higher discounts, and channel dynamics in the U.S., along with foreign exchange headwinds [13]. Key Events - Biogen announced a collaboration with Stoke Therapeutics to develop zorevunersen for Dravet syndrome, with a pivotal study expected to begin in the first quarter of 2025 [14]. Earnings Surprise History - Biogen has consistently beaten earnings estimates in the past four quarters, with an average earnings surprise of 11.8%. However, the current model does not predict a beat for the upcoming quarter, with an Earnings ESP of -15.8% [15][16][17].

Core Viewpoint - C.H. Robinson (CHRW) is expected to report first-quarter 2025 results on April 30, with earnings per share estimated at $1.02, reflecting an 18.6% increase year-over-year, despite a 3.8% downward revision in estimates over the past 60 days [1][2]. Financial Estimates - The Zacks Consensus Estimate for revenues is projected at $4.3 billion, indicating a 2.2% decrease from first-quarter 2024 actuals [1]. - Revenue estimates for the transportation segment are pegged at $4.1 billion, slightly down from the previous year [3]. - North American Surface Transportation revenues are estimated at $3 billion, a 0.7% decline from the year-ago figure [4]. - Global Forwarding segment revenues are anticipated to be $906.4 million, representing a 23.3% increase year-over-year [4]. Operational Insights - CHRW's operational efficiency, driven by cost-cutting initiatives, is expected to positively impact bottom-line performance [5]. - The company has a strong earnings history, surpassing the Zacks Consensus Estimate in the last four quarters with an average beat of 21.7% [2]. Earnings Prediction Model - The current model does not predict an earnings beat for CHRW, as it has an Earnings ESP of +1.36% and a Zacks Rank of 4 (Sell) [6].

Brown & Brown, Inc. (BRO) is expected to register an improvement in its top and bottom lines when it reports first-quarter 2025 results on April 28, after the closing bell.The Zacks Consensus Estimate for BRO’s first-quarter revenues is pegged at $1.4 billion, indicating 11.4% growth from the year-ago reported figure.The consensus estimate for earnings is pegged at $1.30 per share. The Zacks Consensus Estimate for BRO’s first-quarter earnings has moved up 0.7% in the past 30 days. The estimate suggests a ye ...

EQT Corporation (EQT) reported first-quarter 2024 adjusted earnings from continuing operations of $1.18 per share, which beat the Zacks Consensus Estimate of $1.02. The bottom line increased from the year-ago reported figure of 82 cents. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Adjusted operating revenues increased to $2,153 million from $1,720 million in the prior-year quarter. The top line beat the Zacks Consensus Estimate of $2,147 million.The strong quarterly results were ...

ONEOK Inc. (OKE) is scheduled to release first-quarter 2025 results on April 29, after market close. The company delivered an earnings surprise of 8.3% in the last reported quarter. (See the Zacks Earnings Calendar to stay ahead of market-making news.) Let's discuss the factors that are likely to be reflected in the upcoming quarterly results. Key Factors That May Impact OKE's Q1 Results In December 2025, ONEOK completed MB-6, a 125,000-barrel per day (bpd) natural gas liquids (NGL) fractionator in Mont Bel ...

Core Viewpoint - Regeneron Pharmaceuticals is expected to report first-quarter 2025 results on April 29, 2025, with revenue estimates at $3.25 billion and earnings at $8.76 per share. The company has a mixed earnings surprise history, with an average surprise of 3.23% over the last four quarters [1][2]. Financial Performance - The Earnings Surprise Prediction Model indicates a negative Earnings ESP of -0.94%, suggesting a lower likelihood of an earnings beat this quarter [3]. - The Zacks Rank for Regeneron is currently 4 (Sell), indicating a bearish outlook [3]. Product Sales Overview - Eylea, Regeneron's leading drug, is facing sales pressure due to competition from Vabysmo, with expected sales in the U.S. pegged at $1.2 billion for the first quarter [4][5][6]. - The introduction of Eylea HD is anticipated to have positively impacted total Eylea franchise sales due to strong demand [6]. - Dupixent is another significant revenue driver, with sales estimates at $3.7 billion, bolstered by strong prescription trends and recent label expansions [7][8]. - Libtayo's sales are projected at $346 million, driven by increased demand in non-melanoma skin indications and lung cancer treatments [10]. Regulatory and Pipeline Updates - Regeneron received European Commission approval for odronextamab, enhancing its oncology portfolio [11]. - The FDA approved a label expansion for Dupixent, while a complete response letter was issued regarding the extended dosing intervals for Eylea HD [14][15][16]. - The FDA accepted a supplemental biologics license application for Eylea HD, with a target action date set for August 19, 2025 [17]. Shareholder Returns - In February 2025, Regeneron initiated a quarterly cash dividend program at $0.88 per share and authorized a $3.0 billion share repurchase program, totaling approximately $4.5 billion [13]. Market Performance - Regeneron's shares have declined by 21.1% year-to-date, compared to a 7.8% decline in the industry [18].

Core Viewpoint - Elevance Health, Inc. reported strong first-quarter 2025 results with adjusted EPS of $11.97, exceeding estimates and showing a year-over-year increase of 10.5% [1][2] Financial Performance - Operating revenues reached $48.8 billion, a 15.4% increase year over year, surpassing consensus estimates by 6% [1][4] - Premiums rose 14.5% year over year to $40.9 billion, exceeding the consensus mark of $38.7 billion [4] - Product revenues increased by 29.1% year over year to $5.8 billion, also beating estimates [4] - Net investment income grew 26.9% year over year to $590 million, surpassing the consensus of $461.3 million [4] - Total expenses were $46.1 billion, up 16.3% year over year, higher than estimates due to increased benefit expenses and operating costs [5] Membership and Operational Update - Medical membership stood at approximately 45.8 million, a 0.5% decline year over year, attributed to Medicaid attrition [3] - The reported membership figure fell short of the Zacks Consensus Estimate of 46.2 million [3] Segment Performance - Health Benefits segment revenues totaled $41.4 billion, an 11.2% year-over-year increase, beating estimates [6] - Carelon segment revenues reached $16.7 billion, a 38% increase year over year, driven by acquisitions and product revenue growth [7] - Corporate & Other segment reported revenues of $165 million with an operating loss of $140 million, wider than the previous year's loss [9] Financial Position - Cash and cash equivalents were $7.5 billion, down from $8.3 billion at the end of 2024 [10] - Total assets increased to $119.7 billion from $116.9 billion at the end of 2024 [10] - Long-term debt decreased to $28.1 billion from $29.2 billion [11] - Total equity grew to $42.6 billion from $41.4 billion at the end of 2024 [11] Capital Deployment - The company repurchased shares worth $880 million in Q1 2025, with $8.4 billion remaining under its buyback authorization [12] - A quarterly dividend of $1.71 per share was paid, totaling $386 million [12] 2025 Outlook - The company reaffirmed adjusted EPS guidance between $34.15 and $34.85, an increase from the 2024 figure of $33.04 [13] - Operating revenues are expected to grow in the high-single to low-double digits from $175.2 billion in 2024 [15] - Medical enrollment is forecasted to be between 45.8 and 46.7 million in 2025 [15]

Core Viewpoint - Colgate-Palmolive Company (CL) is anticipated to report a decline in revenues for the first quarter of 2025, with expected revenues of $4.87 billion, reflecting a 3.8% decrease from the previous year [1] Revenue and Earnings Estimates - The consensus estimate for CL's earnings is 86 cents per share, expected to remain flat year over year, with a slight downward adjustment in the past week [2] - The model predicts a sales decline of 1.7% for the first quarter, with specific declines in various regions: 7.2% in Latin America, 1.5% in North America, 3% in Asia Pacific, and 4% in Africa/Eurasia, while Europe and Pet Nutrition are expected to see increases of 2.8% and 3% respectively [6] Market Challenges - CL's performance is likely impacted by inflationary pressures, foreign currency fluctuations, and weak performance in key regions, particularly in Latin America where currency devaluation has been significant [4] - In North America, the company faces challenges in maintaining pricing power due to increased promotional activity and competitive dynamics, which could further pressure profitability [5] Margin and Profitability - Persistent inflation in raw materials and packaging costs is squeezing margins, limiting the company's ability to reinvest in growth initiatives [7] - Despite these challenges, CL's gross margin is expected to expand by 130 basis points to 61.3% in the first quarter, supported by strong pricing and revenue growth management initiatives [10][9] Stock Performance and Valuation - CL shares have gained 7.8% over the past three months, outperforming the industry average growth of 2% [11] - The company trades at a forward 12-month P/E multiple of 25.16X, which is higher than the industry average of 20.89X and the S&P 500's average of 17.61X, indicating a relatively pricey valuation [14]

Core Viewpoint - Nasdaq, Inc. is expected to report first-quarter 2025 earnings on April 24, with a consensus estimate of 77 cents per share, reflecting a 22.2% year-over-year increase, driven by various factors including organic revenue growth and acquisitions [1][7]. Factors to Consider - Continued organic revenue growth, new sales, and increased revenues from Financial Crime Management Technology and the Adenza acquisition are anticipated to positively impact Nasdaq's fourth-quarter performance [2]. - Non-trading revenues are expected to benefit from improved results in Capital Access Platforms, Financial Technology, and Market Services businesses [2]. Financial Crime Management Technology - Higher value contracts, new sales, price increases for existing clients, and new customer acquisitions, especially from small and medium-sized businesses, are likely to support the Financial Crime Management Technology business [3]. Capital Markets Technology - The inclusion of revenues from Calypso due to the Adenza acquisition, along with higher trade management services revenues and market technology license and support revenues, is expected to boost the Capital Markets Technology business, with revenues projected to increase by 9% to $259.4 million [4]. Capital Access Platforms - Factors such as increased data usage, price hikes on regulated data, higher initial listing fees, new data sales, and growth in trading volume on futures contracts linked to the Nasdaq-100 Index are expected to enhance performance in the Capital Access Platforms division. The revenue estimate for this division is $1.23 billion, indicating a 10.2% increase year-over-year [5]. Expenses - Total expenses for the upcoming quarter are expected to rise due to increased compensation and benefits, professional services, technology infrastructure, and other operational costs, with non-GAAP operating expenses projected to increase by 9.2% year-over-year [6]. Volumes - Nasdaq reported a 21% year-over-year increase in U.S. equity options volume to 935 million contracts, while European options and futures volume rose by 4.6% to 15.9 million contracts. U.S. matched equity volume reached 137.5 billion shares, up 17.8% from the previous year [8][9]. Revenue Estimates - Data and listing services revenues are expected to increase by 5.8% to $196.8 million in the upcoming quarter [10]. Earnings Prediction - Nasdaq has a positive Earnings ESP of +1.32%, indicating a potential earnings beat, supported by a Zacks Rank of 3 [11][12].

Core Viewpoint - Xcel Energy (XEL) is expected to report its first-quarter 2025 results on April 24, with a prior negative earnings surprise of 6.9% in the last quarter [1] Factors Impacting Q1 Earnings - The company is adding new electric and natural gas customers, which is likely to positively impact performance in the upcoming quarter [2] - Demand from data centers, electric vehicle adoption, and economic growth in the service region are expected to benefit quarterly earnings [3] - Increased operation and maintenance expenses may offset some positive factors, with severe windstorms in Texas and New Mexico potentially negatively impacting earnings [3] Earnings Estimates - The Zacks Consensus Estimate for earnings is 96 cents per share, reflecting a year-over-year increase of 9.09% [4] - The consensus revenue estimate is $3.93 billion, indicating a year-over-year improvement of 7.82% [4] Earnings Prediction Model - The current model does not predict an earnings beat for Xcel Energy, with an Earnings ESP of -2.08% and a Zacks Rank of 4 (Sell) [5][6]